Suzanne Fanning

1.3k total citations
44 papers, 320 citations indexed

About

Suzanne Fanning is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Suzanne Fanning has authored 44 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pathology and Forensic Medicine, 23 papers in Genetics and 23 papers in Oncology. Recurrent topics in Suzanne Fanning's work include Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (22 papers) and CAR-T cell therapy research (9 papers). Suzanne Fanning is often cited by papers focused on Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (22 papers) and CAR-T cell therapy research (9 papers). Suzanne Fanning collaborates with scholars based in United States, Germany and Switzerland. Suzanne Fanning's co-authors include Jeff P. Sharman, Kathryn S. Kolibaba, Jason M. Melear, David Andorsky, S Andresen, Ronald Sobecks, BJ Bolwell, Abdulraheem Yacoub, Daruka Mahadevan and Peter Sportelli and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Suzanne Fanning

41 papers receiving 318 citations

Peers

Suzanne Fanning

ONCOL

PFM

GENET

PRM

HEMAT

Eduardo Ríos Spain

Rita Mazza Italy

F. Fiedler Germany

Sandra Bašić‐Kinda Croatia

Mayur Narkhede United States

Nicolò Compagno Switzerland

Maj Westman Denmark

Olivia Minelli Italy

Mary McCauley United States

Eduardo Ríos Spain

Suzanne Fanning

77 ×0.4

ONCOL

109 ×0.6

PFM

73 ×0.5

GENET

22 ×0.3

PRM

70 ×1.1

HEMAT

Citations per year, relative to Suzanne Fanning Suzanne Fanning (= 1×) peers Eduardo Ríos

Countries citing papers authored by Suzanne Fanning

Since Specialization

Citations

This map shows the geographic impact of Suzanne Fanning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Fanning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Fanning more than expected).

Fields of papers citing papers by Suzanne Fanning

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne Fanning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Fanning. The network helps show where Suzanne Fanning may publish in the future.

Co-authorship network of co-authors of Suzanne Fanning

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne Fanning. A scholar is included among the top collaborators of Suzanne Fanning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne Fanning. Suzanne Fanning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Manda, Sudhir, Bertrand Anz, Christopher B. Benton, et al.. (2024). A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia. Hematological Oncology. 42(3). e3274–e3274. 6 indexed citations

Fanning, Suzanne, et al.. (2024). Reconsidering Semaglutide Use for Chronic Obesity in Patients of Asian Descent: A Critical Review. Cureus. 16(11). e73111–e73111.

Babushok, Daria V., Amy E. DeZern, Zora R. Rogers, et al.. (2024). Modified Delphi panel consensus recommendations for management of severe aplastic anemia. Blood Advances. 8(15). 3946–3960. 5 indexed citations

Sehgal, Alison R., Daanish Hoda, Peter A. Riedell, et al.. (2022). Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study.. Journal of Clinical Oncology. 40(16_suppl). 7062–7062. 3 indexed citations

Godwin, John E., César O. Freytes, Michael B. Maris, et al.. (2021). Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) at Nonuniversity Medical Centers (NMCs): Initial Results from the Outreach Study in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL). Transplantation and Cellular Therapy. 27(3). S203–S204. 1 indexed citations

Lansigan, Frederick, David Andorsky, Morton Coleman, et al.. (2021). Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood. 138(Supplement 1). 812–812. 11 indexed citations

Manda, Sudhir, Bertrand Anz, Christopher B. Benton, et al.. (2021). Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia. Blood. 138(Supplement 1). 1265–1265. 3 indexed citations

Sharman, Jeffrey P., Jason M. Melear, Abdulraheem Yacoub, et al.. (2021). INDUCTION R² FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY. Hematological Oncology. 39(S2). 1 indexed citations

Andorsky, David, Morton Coleman, Abdulraheem Yacoub, et al.. (2020). MAGNIFY phase IIIb interim analysis of induction R² followed by maintenance in relapsed/refractory indolent NHL.. Journal of Clinical Oncology. 38(15_suppl). 8046–8046. 8 indexed citations

10.

Coleman, Morton, David Andorsky, Abdulraheem Yacoub, et al.. (2020). Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance. Blood. 136(Supplement 1). 24–25. 4 indexed citations

11.

Flinn, Ian W., David Andorsky, Jason M. Melear, et al.. (2020). Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study. Blood. 136(Supplement 1). 4–5. 2 indexed citations

12.

Rummel, Mathias, David Andorsky, Morton Coleman, et al.. (2019). PS1253 MAGNIFY: PHASE IIIB INTERIM ANALYSIS OF INDUCTION #R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA. HemaSphere. 3(S1). 572–572. 1 indexed citations

13.

Fanning, Suzanne, et al.. (2019). Cognition in Multiple Myeloma Patients. Biology of Blood and Marrow Transplantation. 25(3). S374–S375. 3 indexed citations

14.

Andorsky, David, Morton Coleman, Abdulraheem Yacoub, et al.. (2018). Response rate to lenalidomide plus rituximab (R²) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.. Journal of Clinical Oncology. 36(15_suppl). 7516–7516. 5 indexed citations

15.

Sharman, Jeff P., Charles M. Farber, Daruka Mahadevan, et al.. (2016). Ublituximab ( TG ‐1101), a novel glycoengineered anti‐ CD 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. British Journal of Haematology. 176(3). 412–420. 44 indexed citations

16.

Sharman, Jeff P., Charles M. Farber, Daruka Mahadevan, et al.. (2014). Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial. Blood. 124(21). 4679–4679. 13 indexed citations

17.

Costa, Luciano J., Suzanne Fanning, Joe Stephenson, et al.. (2014). Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia & lymphoma. 56(3). 645–649. 24 indexed citations

18.

Fanning, Suzanne, et al.. (2011). Pulmonary extramedullary haematopoiesis. BMJ Case Reports. 2011. bcr0620114392–bcr0620114392. 5 indexed citations

19.

Baz, Rachid, Suzanne Fanning, Lori Kunkel, et al.. (2007). Combination of rituximab and oral melphalan and prednisone in newly diagnosed multiple myeloma. Leukemia & lymphoma. 48(12). 2338–2344. 11 indexed citations

20.

Fanning, Suzanne, Lisa Rybicki, S Andresen, et al.. (2006). Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. British Journal of Haematology. 135(3). 374–381. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact